Get the Stockscreener App
7.70
1.85%
0.14
Pre-market:
7.67
-0.03
-0.39%
Myriad Genetics Inc stock is traded at $7.70, with a volume of 1.54M.
It is up +1.85% in the last 24 hours and down -5.29% over the past month.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
See More
Previous Close:
$7.56
Open:
$7.55
24h Volume:
1.54M
Relative Volume:
1.17
Market Cap:
$691.29M
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-5.9231
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
+2.67%
1M Performance:
-5.29%
6M Performance:
-56.27%
1Y Performance:
-60.45%
1-Day Range:
$7.36
$7.78
1-Week Range:
$6.94
$7.78
52-Week Range:
$6.94
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
7.70 | 691.29M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
422.27 | 159.05B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.40 | 140.21B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
475.07 | 34.90B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
108.37 | 30.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
152.30 | 26.47B | 15.41B | 1.37B | 2.11B | 7.50 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
PARP Inhibitor Biomarkers Market Top PlayersMyriad Genetics, - openPR.com
Myriad Genetics Quarterly Earnings Preview: What to ExpectNews and Statistics - IndexBox
What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings - Yahoo Finance
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help - Hometown Stations
Press Release Distribution & PR Platform - ACCESS Newswire
Molecular Diagnostics Market to Witness Remarkable Growth with - openPR.com
Myriad Genetics: Significantly Undervalued With Profitability In Sight - Seeking Alpha
Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsight - GlobeNewswire Inc.
Myriad Genetics (MYGN) Survey Highlights Views on Mental Health Medication | MYGN Stock News - GuruFocus
Concerns about Mental Health Medication Side Effects Remain - GlobeNewswire
Mental Health Breakthrough: New Genetic Test Could End Medication Trial-and-Error, Study Shows - Stock Titan
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 - GlobeNewswire
Myriad Genetics Announces Triple Investor Event: Q1 Earnings Plus Two Elite Healthcare Conferences - Stock Titan
10-DAY DEADLINE ALERT” HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Myriad Genetics Highlights MRD Clinical Validity Data at America - GuruFocus
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting - The Manila Times
Breakthrough Cancer Detection Test Achieves 94% Survival Rate, Doubles Treatment Window in Kidney Cancer Study - Stock Titan
3 Healthcare Stocks That Concern Us - Yahoo Finance
Myriad Genetics Unveils Promising Clinical Data on Precise MRD Test for Oligometastatic Clear-Cell Renal Cell Carcinoma at AACR Annual Meeting - Nasdaq
Myriad Genetics stock hits 52-week low at $7.28 amid sharp decline - Investing.com India
Myriad Genetics stock hits 52-week low at $7.28 amid sharp decline By Investing.com - Investing.com South Africa
Microtomes Market Projected To Witness Substantial Growth, - openPR.com
Myriad Genetics (MYGN) Study Shows Reduced Hospitalizations with - GuruFocus
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside? - Yahoo Finance
Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing | MYGN Stock News - GuruFocus
Myriad Genetics (MYGN) Study Shows Reduced Hospitalizations with GeneSight Test | MYGN Stock News - GuruFocus
Myriad Genetics Study Finds GeneSight Test Reduces Psychiatric Hospitalizations in Major Depressive Disorder Patients - Nasdaq
Myriad Genetics Announces Study Results Show Patients with - GlobeNewswire
New Study: Depression Patients See 40% Drop in Drug Complications with GeneSight Genetic Test - Stock Titan
Demystifying Myriad Genetics: Insights From 10 Analyst Reviews - Benzinga
Pancreatic Cancer Market Growth, Trends & Forecast 2024-2031 | - openPR.com
Myriad Genetics price target lowered to $9 from $11 at BofA - Yahoo Finance
Myriad Genetics (MYGN) Sees Price Target Lowered by BofA Amid Po - GuruFocus
8-DAY DEADLINE ALERT” HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Genetic Screening Testing for Preventive Health Market Top - openPR.com
Myriad Genetics price target lowered to $19 from $27 at Raymond James - MSN
Guggenheim Downgrades Myriad Genetics to Neutral From Buy - marketscreener.com
Myriad Genetics Announces Inducement Awards - The Manila Times
Myriad Genetics Announces Inducement Awards | MYGN Stock News - GuruFocus
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):